CVRx, Inc. (NASDAQ:CVRX) Insider Paul Verrastro Sells 1,430 Shares

CVRx, Inc. (NASDAQ:CVRX) insider Paul Verrastro sold 1,430 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $13.58, for a total transaction of $19,419.40. Following the completion of the sale, the insider now owns 1,875 shares of the company’s stock, valued at approximately $25,462.50. The trade was a 43.27 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

CVRx Trading Down 0.1 %

Shares of NASDAQ:CVRX traded down $0.01 during mid-day trading on Friday, reaching $14.76. The stock had a trading volume of 58,813 shares, compared to its average volume of 276,552. CVRx, Inc. has a twelve month low of $6.40 and a twelve month high of $33.13. The firm has a market cap of $358.08 million, a PE ratio of -5.44 and a beta of 1.16. The company has a current ratio of 11.32, a quick ratio of 10.23 and a debt-to-equity ratio of 0.76. The firm has a 50 day simple moving average of $10.76 and a two-hundred day simple moving average of $9.67.

CVRx (NASDAQ:CVRX) last posted its quarterly earnings data on Tuesday, October 29th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.12). The company had revenue of $13.37 million during the quarter, compared to the consensus estimate of $13.28 million. CVRx had a negative net margin of 123.75% and a negative return on equity of 89.06%. During the same period in the prior year, the firm posted ($0.43) earnings per share. On average, research analysts predict that CVRx, Inc. will post -2.62 EPS for the current fiscal year.

Institutional Investors Weigh In On CVRx

A number of institutional investors and hedge funds have recently made changes to their positions in CVRX. SG Americas Securities LLC bought a new stake in CVRx during the third quarter worth $108,000. XTX Topco Ltd acquired a new stake in shares of CVRx during the third quarter worth $150,000. Rhumbline Advisers boosted its position in shares of CVRx by 28.8% in the second quarter. Rhumbline Advisers now owns 17,260 shares of the company’s stock valued at $207,000 after acquiring an additional 3,863 shares during the period. Dimensional Fund Advisors LP acquired a new position in shares of CVRx in the second quarter valued at about $218,000. Finally, Jane Street Group LLC increased its position in CVRx by 36.1% during the third quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock worth $168,000 after acquiring an additional 5,053 shares during the period. Institutional investors own 75.27% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CVRX. Lake Street Capital raised their price objective on shares of CVRx from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $14.00 target price on shares of CVRx in a research note on Wednesday, October 23rd. Piper Sandler reissued an “overweight” rating and set a $16.00 target price (up previously from $13.00) on shares of CVRx in a research report on Wednesday, October 30th. Canaccord Genuity Group raised their target price on CVRx from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, Craig Hallum raised their price objective on shares of CVRx from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, November 4th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, CVRx has a consensus rating of “Moderate Buy” and a consensus price target of $15.83.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.